ATE407684T1 - Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels - Google Patents

Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Info

Publication number
ATE407684T1
ATE407684T1 AT02757918T AT02757918T ATE407684T1 AT E407684 T1 ATE407684 T1 AT E407684T1 AT 02757918 T AT02757918 T AT 02757918T AT 02757918 T AT02757918 T AT 02757918T AT E407684 T1 ATE407684 T1 AT E407684T1
Authority
AT
Austria
Prior art keywords
antibody
polyplex
therapeutic
antibody fragment
diagnostic agent
Prior art date
Application number
AT02757918T
Other languages
English (en)
Inventor
Esther Chang
Kathleen Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE407684T1 publication Critical patent/ATE407684T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02757918T 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels ATE407684T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28013401P 2001-04-02 2001-04-02

Publications (1)

Publication Number Publication Date
ATE407684T1 true ATE407684T1 (de) 2008-09-15

Family

ID=23071820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757918T ATE407684T1 (de) 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Country Status (7)

Country Link
EP (1) EP1408996B1 (de)
AT (1) ATE407684T1 (de)
AU (1) AU2002307035A1 (de)
CA (1) CA2442533C (de)
DE (1) DE60228842D1 (de)
ES (1) ES2312608T3 (de)
WO (1) WO2002078608A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617514B2 (en) * 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US20110020373A1 (en) * 2006-03-30 2011-01-27 The Regents Of The University Of California Ige directed dna vaccination
US20070292497A1 (en) * 2006-05-04 2007-12-20 Martin Francis J Method for treating micrometastatic tumors
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CN113384712A (zh) * 2021-06-11 2021-09-14 潍坊医学院 一种基于同时杀伤肿瘤细胞和CAFs的共载脂质体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642980B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
CA2194221C (en) * 1994-06-22 2001-01-02 Megabios Corporation Cationic amphiphiles
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
WO1997000271A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
AU4090299A (en) * 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
AU3703100A (en) * 1999-02-22 2000-09-14 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery

Also Published As

Publication number Publication date
EP1408996A2 (de) 2004-04-21
ES2312608T3 (es) 2009-03-01
DE60228842D1 (de) 2008-10-23
WO2002078608A2 (en) 2002-10-10
AU2002307035A1 (en) 2002-10-15
EP1408996A4 (de) 2006-03-22
WO2002078608A8 (en) 2004-06-03
CA2442533A1 (en) 2002-10-10
WO2002078608A3 (en) 2004-02-26
EP1408996B1 (de) 2008-09-10
CA2442533C (en) 2014-02-04

Similar Documents

Publication Publication Date Title
TW200621801A (en) Antibody molecules having specificity for human IL-17
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
DE602005016148D1 (de) Targetingmittel für molekulare bilderzeugung
DE50004742D1 (de) Verfahren zur herstellung von polyetherpolyolen
ATE449153T1 (de) Verfahren zur herstellung eines waschmittels
ATE288502T1 (de) Gezieltes antikörper-verfahren
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE432063T1 (de) Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft
DE50104476D1 (de) Gekühltes Bauteil, Gusskern für die Herstellung eines solchen Bauteils, sowie Verfahren zum Herstellen eines solchen Bauteils
WO2006130773A3 (en) Methods of treating brain tumors with antibodies
ATE278390T1 (de) Verfahren zur herstellung von arzneistoffpartikeln
DE50007641D1 (de) Verfahren zur herstellung von polyetheralkoholen
WO2021189047A3 (en) Extracellular vesicles for therapy
DE60228842D1 (de) Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels
EA200301271A1 (ru) Способ диагностики или прогнозирования основных респираторных бактериальных патогенов у субъекта
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
DE60218473D1 (de) Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
DE602006000666D1 (de) Vorrichtung und Verfahren zur Herstellung von wellenförmigen Bändern
ATE259379T1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
ATE322891T1 (de) Arzneistoffabgabesystem für wasser schwerlösliche arzneimittel
DE60308066D1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
DE69912827T2 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
ATE416155T1 (de) Verfahren zur herstellung von bis-ä(3- dimethylamino)propylüamin (bisdmapa)
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
ATE325794T1 (de) Verfahren zur herstellung und zwischenprodukte von pyridin-2-yl-amin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties